Robert Hofmeister
Chief Scientific Officer CREATE Medicines
Dr Hofmeister joined Create Medicines in February 2024. Previously, he was the CSO at Resonance Medicine, where he drove the development of their research and development strategy, leveraging their therapeutic modality. Previously, he served as CSO at TCR2 Therapeutics, where he started as employee number one and was instrumental in building and leading the R&D function, driving the development of their proprietary TRuC®-T cell platform from concept to first-cleared IND (TC-210 program). He successfully contributed to taking the company public as well as securing multimillion dollar rounds of fundraising.
Seminars
Saturday 29th August 2026
Developing a Multi-Lineage In Vivo CAR Platform Expanding Impact Across Autoimmunity & Solid Tumors
10:00 am
- Engineering myeloid, NK, and CAR-T programs with cell specific activity, enabling precise immune cell programming and broader therapeutic reach across indications
- Implementing repeatable RNA-LNP delivery to achieve deep lymph node depletion and immune reset, supporting translation of autoimmune concepts into first-in-human readiness
- Combining CAR-T and myeloid programming with emerging targeted LNPs and stable genomic integration systems, strengthening future strategies for solid tumor control and long-term clinical durability
